The Peptide Boom: What's Actually Approved, What Isn't, and What the Science Shows

Peptide use has expanded rapidly across consumer wellness markets over the past several years. The category now spans FDA-approved prescription drugs, compounds prepared through compounding pharmacies, and a large secondary market of substances labeled "for research use only." This article summarizes what peptides are, the regulatory framework—and loophole—that most peptides are sold under, the risks that follow from it, and the evidence base for the most commonly used peptides.

What is a peptide?

The line between a peptide and a protein isn't exact, but scientists generally think of peptides as very small protein fragments. Peptides can function as signaling molecules, acting as messengers within the body to influence biological processes. Insulin, human growth hormone, GLP-1s, and oxytocin are all peptides.¹

In the wellness world, the term "peptide" usually refers to a specific group of compounds—sold most often as injections, but also as nasal sprays, capsules, or topicals—that have surged in popularity in recent years.¹ These fall into four regulatory categories:

1. FDA-approved peptide drugs, including GLP-1s like semaglutide and tirzepatide, tesamorelin, and bremelanotide.
2. Peptides approved for compounding under the FDA's Category 1 list, including popular peptides like BPC-157 and TB-500. These peptides are not approved as new drugs, but are available via prescription through a compounding pharmacy at a physician's discretion.
3. Unapproved peptides, often sold under "for research purposes." These represent a large part of the emerging consumer market.
4. Naturally derived peptides sold as dietary supplements, of which collagen and creatine peptides are the principal examples—permitted because of their long history of dietary use.

The regulatory landscape

The "research use only" workaround

Federal law prohibits companies from marketing medications that haven't been approved through a highly regulated system requiring extensive clinical studies to prove safety and efficacy. That includes most peptides, which are regulated as small molecules rather than dietary supplements (with collagen and creatine peptides as the notable exceptions). The law does not, however, prevent labs from producing peptides for research purposes.

Increasingly, many peptides circulating in the consumer marketplace are sold by online companies that label their products "for research use only" or "not for human consumption"—a legal workaround that allows them to subvert the legal regulatory pathway, and a cause for concern when it comes to safety and quality.¹^,²

The FDA compounding framework

A second pathway runs through 503A compounding pharmacies—facilities licensed to prepare custom medications for individual patients with a prescription. Compounded peptides must either start from an existing FDA-approved drug or use a substance on the FDA's 503A bulks list (a group of substances deemed safe and effective for compounding).³ The FDA categorizes substances into two categories: Category 1 substances are eligible for compounding with a valid prescription. Category 2 substances are not, because the FDA considers them to carry "significant safety risks."

Between late 2023 and early 2026, the FDA launched the most aggressive regulatory campaign the peptide industry has faced. Nineteen peptides were moved from the Category 1 list to the Category 2 list, deeming them too dangerous for compounding pharmacies to prepare. These included commonly used peptides from the biohacking industry, BPC-157, Thymosin Alpha-1, TB-500 (Thymosin Beta-4), CJC-1295, ipamorelin, AOD-9604, Selank, Semax, KPV, MOTS-C, and GHK-Cu.⁴ The FDA cited "significant safety concerns" for each, specifically immunogenicity risks and the absence of adequate human clinical data.²

The Category 2 designation removed the option of obtaining these peptides through a compounding pharmacy with a prescription, leaving the unregulated research peptide market as the only remaining source—a paradox in which restrictions intended to protect consumers pushed them toward a less regulated supply chain.²

Recently, many of those peptides were moved back to Category 1 by HHS Secretary Robert F. Kennedy Jr., making them eligible for prescription from a physician, and manufactured by a compounding pharmacy. These include BPC-157, Thymosin Alpha-1, TB-500 (Thymosin Beta-4), CJC-1295 and Ipamorelin, AOD-9604, Selank and Semax, KPV, MOTS-C, and GHK-Cu.

Why FDA approval matters

FDA approval reduces the risk profile of a peptide in three substantive ways:⁵

Manufacturing oversight. FDA-approved drugs, including peptides, must adhere to strict manufacturing standards, called cGMP. Egrifta (tesamorelin), for example, is produced under cGMP standards that the FDA audits regularly. Compounded peptides from research suppliers are not held to the same standard.

Safety data. The FDA approval process requires three phases of clinical studies demonstrating both safety and efficacy. For example, Egrifta required two Phase 3 randomized controlled trials with over 800 participants, plus long-term extension studies. That level of human safety data does not exist for popular peptides like ipamorelin, CJC-1295, or HGH Fragment 176-191.

Legal prescribing. Once a drug has FDA approval for any indication, licensed physicians can legally prescribe it for other conditions they deem medically appropriate, with specific dosage recommendations that have been supported by large clinical studies. Without FDA approval, a compound cannot be prescribed at all through traditional pharmacy channels, and dosages are largely unexplored.

The concerns around unapproved peptides

For unapproved peptides sold as research chemicals, there are a few primary concerns with regards to safety.

Untested in humans

Some of the most popular peptides have never been tested in formal human trials. They are sold for research purposes, not human consumption. While many peptides show compelling animal data, the absence of human clinical trials leaves fundamental questions unanswered—proper dosage, length of treatment, best route of administration, and side effects—and forces clinicians to develop their own protocols.¹

Quality control problems

Research peptide vendors operate outside pharmaceutical manufacturing standards. There is no FDA inspection, no GMP certification, and no third-party purity verification required.

Finnrick Analytics, a peptide-testing startup in Austin, Texas, has analyzed the purity and potency of more than 5,000 samples of 15 different peptides from 173 vendors. The results show that quality varies substantially from vendor to vendor and even batch to batch. In one analysis of nearly 450 samples of BPC-157 from 64 vendors, some vials sold as BPC-157 did not contain the compound at all. In those that did, purity varied from about 82% to 100%. Perhaps most concerning, 8% of all samples tested contained measurable levels of endotoxins—bacterial fragments that can cause fever and chills or, in larger doses, septic shock.¹

Unknown side effects

The side effects and long-term effects of most research peptides remain uncharacterized. Some researchers have warned that peptides that promote growth or blood vessel formation might also foster the growth of cancers.¹

The main peptides on the market

The peptides currently in circulation vary in their evidence base, regulatory status, and route of administration. The following is a category-by-category breakdown.

GLP-1 receptor agonists (injectable, FDA-approved)

GLP-1 receptor agonists are among the most clinically validated peptides on the market. Originally developed as diabetes treatments, they promote weight loss by slowing digestion and increasing feelings of fullness. The class includes exenatide (Byetta, Bydureon), lixisenatide (Lyxumia), liraglutide (Victoza), dulaglutide (Trulicity), albiglutide (Tanzeum), and semaglutide (Ozempic). Today, the most widely used peptides for weight loss are tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy).⁶ These compounds are backed by large-scale randomized controlled trials and have full FDA approval.

Growth hormone secretagogues (injectable, mixed approval status)

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the 44-amino-acid peptide the hypothalamus produces to signal the pituitary gland. It is FDA-approved for the reduction of excess abdominal fat in HIV-positive adults with lipodystrophy, and is the only growth hormone-releasing hormone analog with active FDA approval in the United States. The pivotal Phase 3 trial showed visceral adipose tissue decreased by 15.2% in the tesamorelin group versus 5.0% in the placebo group.⁵

Sermorelin, ipamorelin, and CJC-1295 are widely used in anti-aging and body composition protocols. None hold active FDA approval for any indication.⁵ CJC-1295 and ipamorelin were among the peptides reclassified to the Category 2 list as too dangerous for compounding pharmacies to prepare, but both were recently moved back to Category 1.⁴

Healing and recovery peptides (injectable, unapproved, some Category 1)

BPC-157 and TB-500 (Thymosin Beta-4) are the two most widely used healing peptides. While both were placed on the Category 2 list with the rationale that neither has been through human clinical trials sufficient to establish safety, they were recently moved back to Category 1, making them eligible for compounding and accessible through a prescription. BPC-157 has extensive animal data and some limited human data, and TB-500 has some human research.²

The most recent systematic review of BPC-157 analyzed 36 studies published from 1993 to 2024. BPC-157 was shown to promote healing by boosting growth factors and reducing inflammation, with improved outcomes in muscle, tendon, ligament, and bone injury models in animals. In one small human study, 7 of 12 people with chronic knee pain reported relief lasting over six months after a single BPC-157 knee injection. Animal studies showed no harmful effects, but no large-scale clinical safety data in humans is available.⁷

The foundational science for TB-500 comes from a 2004 study in Nature, which reported that thymosin beta-4 promotes cardiomyocyte migration, survival, and repair, and identified the pathway it regulates as a potential therapeutic target in acute myocardial damage.⁸

Immune and anti-aging peptides (injectable, unapproved, some Category 1)

Thymosin Alpha-1 presents a unique case. Similar to BPC-157 and TB-500, it was recently moved from Category 2 to Category 1 in the United States, but is approved as a drug (brand name Zadaxin) in more than 30 countries for hepatitis B and as an immune adjunct during cancer treatment. More than 11,000 patients have been studied in clinical trials, and the Category 2 designation struck many physicians as inconsistent with the available evidence.² Thymosin Alpha-1 has been investigated for its effects on immune function, including the treatment of hepatitis B, treatment of infections, improvement of vaccine efficacy, and reduction of chemotherapy toxicity.⁹

Peptides for general wellness (injectable, unapproved, some Category 1)

MOTS-C is a naturally occurring mitochondrial peptide composed of 16 amino acids that has been studied for metabolic regulation, and was recently placed back on the Category 1 list. Most research has been in rodent models, with limited human studies suggesting it may improve metabolic function, reduce inflammation, and improve bone health.^10,11,12

KPV is an anti-inflammatory tripeptide with potential gut health applications.² It is also available as a Category 1 compound.

Epitalon (Epithalon) is a four-amino-acid peptide studied for its effects on telomere length and melatonin regulation, with possible implications for age-related disease, immune function, and sleep.^13,14,15

AOD-9604 is a peptide fragment studied for fat metabolism, and is now available as a Category 1 peptide for compounding.⁴

Cognitive peptides (intranasal/injectable, unapproved, some Category 1)

Selank and Semax are neuropeptides used clinically in Russia for cognitive function and anxiety.² Selank has been studied for stable and sustained effects on learning and memory, while Semax has been studied for its potential to support the differentiation, maturation, and survival of neurons in the brain.^16,17 Both are now available as Category 1 compounds.

Pinealon is another candidate cognitive peptide. In rodents, pinealon administration has correlated with improved maze navigation, suggesting effects on the acquisition and retention of information through modulation of gene expression and neurotransmitter activity.¹⁸

Sleep peptides (injectable, unapproved)

Delta sleep-inducing peptide (DSIP) has been studied for effects on sleep. It may also attenuate stress and has been investigated for anticonvulsant, antidepressant, and neuroprotective applications.¹⁹

Sexual function (injectable, FDA-approved)

Bremelanotide (PT-141) received FDA approval on June 21, 2019, under the brand name Vyleesi. The approval covers one specific indication: hypoactive sexual desire disorder (HSDD) in premenopausal women.^20,21

Insulin (injectable, FDA-approved)

Insulin is a peptide used to manage blood sugar—helpful for people with type 2 diabetes and necessary for those with type 1 diabetes.²²

Collagen peptides (ingestible, sold as supplements)

Collagen peptides occupy a different regulatory category entirely. They are legally sold as supplements because they are derived from animal food sources and have a long history of dietary use. They are not synthetic, and they are not designed to produce a pharmacological effect.²

GHK-Cu (topical and injectable, unapproved, Category 1)

GHK-Cu is a copper-binding tripeptide that has been studied for tightening loose skin, improving skin firmness, reducing photodamage, and promoting wound healing. The body of preclinical work is extensive; human clinical data for the injectable form remains sparse.^23,24,25

GHK-Cu in its injectable form was placed on the Category 2 list, but was recently moved back to Category 1.⁴ The injectable evidence base has a critical gap: no published human randomized trial has evaluated injectable GHK-Cu for cosmetic, hair, or wound endpoints, and no long-term safety trial exists for injectable use.²⁶ Topical applications of GHK-Cu, by contrast, have a substantial cosmetic track record supported by human studies.²⁷

Topical vs. injectable

The route of administration determines what a peptide can do, where it acts, and what kind of risk profile it carries.

Injectable peptides are delivered directly into the bloodstream or subcutaneous tissue to induce systemic effects. They circulate through the body, signaling through receptors in multiple organ systems. This is why GLP-1 receptor agonists affect the pancreas, stomach, and brain simultaneously. It is also why concerns about contamination, dosing, and unknown long-term effects carry particular weight: a contaminated or impure injectable enters systemic circulation.

Topical peptides are applied to the skin and act locally. Their effects are targeted to the tissue at the site of application, and they do not induce the systemic exposure that injectables do. Well-studied topical peptides can be engineered specifically to act on skin biology without entering the bloodstream.²⁸

Ingestible peptides are a smaller category that includes collagen and creatine peptides, both of which are broken down into amino acids and small fragments during digestion. They are regulated as supplements and are not designed to produce pharmacological effects.²

Other delivery modes include intranasal formulations (commonly used for Selank and Semax in Russian clinical practice) and inhaled formulations (used for some insulin products). These tend to be less common and are often selected to bypass the gut, which destroys most peptides during digestion.

How the OS-01 Peptide™ is different

The OS-01 Peptide™ is a topical peptide developed to target a root cause of skin aging: cellular senescence. Senescent cells are a hallmark of aging: they accumulate in tissues over time and secrete inflammatory signals that degrade tissue structure. The OS-01 Peptide™ is designed to act on this biology directly at the site of application.

OS-01 Peptide™ has been shown not to enter systemic circulation when applied topically, meaning it acts only on the skin and does not produce direct systemic effects like injectable peptides.²⁸

Its mechanism is targeted to skin biology. The OS-01 Peptide™ has been shown to reduce senescent cells in skin, promote collagen and hyaluronic acid synthesis, and support barrier function.²⁹

Its efficacy and safety have been demonstrated in multiple clinical studies. Unlike most of the injectable peptides discussed above—which rely heavily on animal data and have limited or no human RCT evidence—topical application of OS-01 has been evaluated in published clinical studies in peer-reviewed dermatology journals.^30,31,28

References

1. MIT Technology Review. "Peptides are everywhere. Here's what you need to know." February 23, 2026. Link
2. Peptides Explorer. "FDA Peptide Crackdown 2026." Link
3. Innerbody. "Beginner's Guide to Peptide Therapy." Link
4. Amanecia Health. "FDA Peptide Reclassification 2026." Link
5. Peptides Explorer. "Is Tesamorelin FDA Approved?" Link
6. National Institutes of Health / PubMed Central. "GLP-1 receptor agonists." Link
7. Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS Journal, 2025. Link
8. Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature, 2004. Link
9. National Institutes of Health / PubMed Central. "Thymosin Alpha-1 and immune function." Link
10. Cell Metabolism. "MOTS-c, a mitochondrial-derived peptide regulating metabolic homeostasis." Link
11. PubMed. "MOTS-c and inflammation." Link
12. Frontiers in Physiology. "MOTS-c and bone health." Link
13. Journal of Biochemistry. "Epitalon and telomere preservation." Link
14. Johns Hopkins Medicine. "Immune cells age and die prematurely in people with very short telomeres." March 2019. Link
15. Mayo Clinic. "Melatonin." Link
16. Springer. "Selank: effects on learning and memory." Link
17. National Institutes of Health / PubMed Central. "Semax: neuronal differentiation and survival." Link
18. Springer. "Pinealon: cognitive effects in rodent models." Link
19. European Journal of Anaesthesiology. "Delta sleep-inducing peptide." 2001. Link
20. Cenexa Labs. "PT-141 (Bremelanotide): Melanocortin Receptor Agonist." Link
21. Form Blends. "PT-141 Bremelanotide and Sexual Dysfunction." Link
22. Mayo Clinic. "Diabetes treatment: Using insulin to manage blood sugar." Link
23. International Journal of Molecular Sciences. "Regenerative and Protective Actions of the GHK-Cu Peptide." Pickart L, Margolina A. Link
24. BioMed Research International. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." Pickart L, Vasquez-Soltero JM, Margolina A. Link
25. Journal of Investigative Dermatology. "Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+." Maquart FX, Pickart L, et al. Link
26. Peptide Dosing Protocols. "GHK-Cu Protocol." Link
27. Dermatological Reviews. "Topical GHK-Cu in cosmetic dermatology." Link
28. Journal of Cosmetic Dermatology. "OS-01 Peptide topical application and systemic exposure." Link
29. npj Aging. "OS-01 Peptide effects on cellular senescence, collagen, hyaluronic acid synthesis, and barrier function." Link
30. Journal of Cosmetic Dermatology. "OS-01 Peptide clinical study." Link
31. International Journal of Cosmetic Science. "OS-01 Peptide clinical study." Link